Skip to main content
Media Coverage

Enveric Biosciences to out-license psilocin prodrug to MindBio [Pharmaceutical Technology]

By May 15, 2024No Comments

Enveric Biosciences has entered a non-binding term sheet with MindBio Therapeutics for the out-licensing of a class of psilocin prodrugs (NPP) aimed at treating mental health disorders. The NPP molecules are created to metabolise and release therapeutic systemic psilocin levels at varying rates.

Full Article >>